NASDAQ:IOSP - Innospec Stock Price, Forecast & News

Innospec trades on the NASDAQ under the ticker symbol "IOSP."

Innospec announced a Semi-Annual dividend on Tuesday, November 5th. Investors of record on Tuesday, November 19th will be paid a dividend of $0.52 per share on Wednesday, November 27th. The ex-dividend date is Monday, November 18th. This is a boost from Innospec's previous Semi-Annual dividend of $0.50. View Innospec's Dividend History.

Innospec Inc. (NASDAQ:IOSP) posted its quarterly earnings results on Tuesday, February, 18th. The specialty chemicals company reported $1.47 EPS for the quarter, beating the consensus estimate of $1.38 by $0.09. The specialty chemicals company earned $390.70 million during the quarter, compared to analyst estimates of $400.45 million. Innospec had a return on equity of 14.69% and a net margin of 7.41%. The firm's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.62 EPS. View Innospec's Earnings History.

Innospec is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Innospec.

1 analysts have issued 12 month target prices for Innospec's shares. Their forecasts range from $95.00 to $95.00. On average, they expect Innospec's share price to reach $95.00 in the next year. This suggests a possible upside of 9.8% from the stock's current price. View Analyst Price Targets for Innospec.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innospec in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Innospec.

Media headlines about IOSP stock have trended positive this week, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Innospec earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the specialty chemicals company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Innospec.

Innospec saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 391,900 shares, an increase of 6.7% from the January 15th total of 367,400 shares. Based on an average daily volume of 98,700 shares, the days-to-cover ratio is currently 4.0 days. Approximately 1.6% of the shares of the company are sold short. View Innospec's Current Options Chain.

Some companies that are related to Innospec include Ecolab (ECL), Sherwin-Williams (SHW), International Flavors & Fragrances (IFF), Celanese (CE), Albemarle (ALB), RPM International (RPM), Ashland Global (ASH), NewMarket (NEU), W. R. Grace & Co (GRA), Balchem (BCPC), Quaker Chemical (KWR), PolyOne (POL), Sensient Technologies (SXT), HB Fuller (FUL) and Stepan (SCL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innospec investors own include Intellia Therapeutics (NTLA), Las Vegas Sands (LVS), Altria Group (MO), Exxon Mobil (XOM), NVIDIA (NVDA), Franklin Resources (BEN), Colgate-Palmolive (CL), Eastman Chemical (EMN), Emerson Electric (EMR) and Invesco (IVZ).

Innospec's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (11.72%), State Street Corp (2.90%), Champlain Investment Partners LLC (2.71%), Royce & Associates LP (2.42%), Geode Capital Management LLC (1.47%) and Bank of New York Mellon Corp (1.25%). Company insiders that own Innospec stock include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Ian Malcolm Mcrobbie, Milton C Blackmore, Patrick Williams, Philip Curran and Philip John Boon. View Institutional Ownership Trends for Innospec.

IOSP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Wilshire Securities Management Inc., NWQ Investment Management Company LLC, Bank of New York Mellon Corp, Royce & Associates LP, Westwood Holdings Group Inc. and SG Americas Securities LLC. Company insiders that have sold Innospec company stock in the last year include Brian Watt, Catherine Hessner, Hugh Aldous, Ian Cleminson, Patrick Williams, Philip Curran and Philip John Boon. View Insider Buying and Selling for Innospec.

IOSP stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, James Investment Research Inc., Thrivent Financial for Lutherans, Great West Life Assurance Co. Can, Bank of Montreal Can, Citigroup Inc., Mackay Shields LLC and First Trust Advisors LP. View Insider Buying and Selling for Innospec.

Shares of IOSP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOSP stock can currently be purchased for approximately $86.54.

Innospec has a market capitalization of $2.12 billion and generates $1.51 billion in revenue each year. Innospec employs 2,000 workers across the globe.View Additional Information About Innospec.

The official website for Innospec is http://www.innospecinc.com/.

Innospec's mailing address is 8310 SOUTH VALLEY HIGHWAY SUITE 350, ENGLEWOOD CO, 80112. The specialty chemicals company can be reached via phone at 303-792-5554 or via email at [email protected]